UK. GW Pharmaceuticals have announced a US patent for cannabinoids to shrink brain tumours
GW Pharmaceuticals have announced a US patent for the use of cannabis as a treatment for Glioma, one of the most common forms of brain cancer.
The Press Release on the GW Pharma website explains more
"The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent from this application will provide an exclusivity period until June 2029."
In simple terms this means that GW feel that CBD plays an important role in the treatment and shrinking of brain tumours. A 1:1 ratio of THC:CBD is the same ratio of cannabinoids seen in varieties such as Dutch Passion CBD SkunkHaze. It is also the same ratio used in GW Pharma's Sativex product. This product is now licensed in 20+ countries for treating epilepsy. The GW patent also mentions a 1:20 ratio of THC:CBD. This infers that a CBD dominant cannabis extract is of value (and suggests THC may be lessuseful than CBD).
What will be of most interest is the peer reviewed clinical trial data, once this is available. That data will show whether there is statistical correlation which will support the use of cannabinoids in the treatment of brain tumours.
All the details are available here, on the GW Pharma website https://www.gwpharm.com/GW%20Pharmaceuticals%20plc%20Announces%20US%20Patent%20Allowance%20for%20Use%20of%20Cannabinoids%20in%20Treating%20Glioma.aspx
Medical cannabis supporters will be encouraged to see research into cannabis uses for treating cancer, any positive results from future studies will be seized upon by medical marijuana campaigners.
December 14th 2013